Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
MOUNTAIN VIEW, Calif., March 01, 2017 -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2017 to discuss these results and to answer questions.
To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 80376833. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases, and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare kidney diseases, avacopan (CCX168) and CCX140.
Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). In clinical studies to date, avacopan was shown to be safe, well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. Avacopan is also being developed in patients with C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for AAV, and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of AAV: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis). Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need.
The Company's other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease.
ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China.
ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Source: ChemoCentryx, Inc.
Contacts: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer [email protected] Media: Denise Powell [email protected] 510.703.9491 Investors: Steve Klass Burns McClellan 212.213.0006 [email protected]
